Bibliography: library/10665-385346

The reference for library/10665-385346 (who-iris) and any references extracted from it. library · All references.

Export these 10 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

10 shown

  1. Khadijeh Ezoji; Mohsen Yaghoubi; Marzieh Nojomi; et al. (2019). Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran. World Health Organization. Regional Office for the Eastern Mediterranean.
    10665-385346 · catalogue · link · doi:https://doi.org/10.26719/emhj.19.039 · repository record · source: catalogue/records/10665-385346.dc.json · held: library/10665-385346
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumo-niae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893-902.
    · extracted · source: references/10665-385346.page-011.1.json
  3. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RAN, Nohynek H, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;(4):CD004977.
    · extracted · source: references/10665-385346.page-011.2.json
  4. Ordonez JE, Orozco JJ. Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia. BMC Infect Dis. 2014;14(1):172.
    · extracted · source: references/10665-385346.page-011.3.json
  5. Wu DB-C, Chang C-J, Huang Y-C, Wen Y-W, Wu C-L, Fann CS-J. Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach. Value Health. 2012;15(1 Suppl):S15-S9.
    · extracted · source: references/10665-385346.page-011.4.json
  6. Gonzalez-Moro JMR, Menéndez R, Campins M, Lwoff N, Oyagiiez I, Echave M, et al. Cost effectiveness of the 13-valent pneu-mococcal conjugate vaccination program in chronic obstructive pulmonary disease patients aged 50+ years in Spain. Clin Drug Investig. 2016;36(1):41-53.
    · extracted · source: references/10665-385346.page-011.5.json
  7. Mezones-Holguin E, Canelo-Aybar C, Clark AD, Janusz CB, Jatiregui B, Escobedo-Palza S, et al. Cost-effectiveness analysis of 10-and 13-valent pneumococcal conjugate vaccines in Peru. Vaccine. 2015;33:A154-A66.
    · extracted · source: references/10665-385346.page-011.6.json
  8. Constenla DO. Post-introduction economic evaluation of pneumococcal conjugate vaccination in Ecuador, Honduras, and Para-guay. Rev Panam Salud Publica. 2015;38(5):388-95.
    · extracted · source: references/10665-385346.page-011.7.json
  9. Marti SG, Colantonio L, Bardach A, Galante J, Lopez A, Caporale J, et al. A cost-effectiveness analysis of a 10-valent pneumococ-cal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc. 2013511(1):1.
    · extracted · source: references/10665-385346.page-011.8.json
  10. Sibak M, Moussa I, El-Tantawy N, Badr S, Chaudhri I, Allam E, et al. Cost-effectiveness analysis of the introduction of the pneu-mococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013. Vaccine. 2015;33:A182-A191.
    · extracted · source: references/10665-385346.page-011.9.json